1. Home
  2. UFCS vs SDGR Comparison

UFCS vs SDGR Comparison

Compare UFCS & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo United Fire Group Inc.

UFCS

United Fire Group Inc.

HOLD

Current Price

$51.39

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

SDGR

Schrodinger Inc.

HOLD

Current Price

$15.13

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UFCS
SDGR
Founded
1946
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
UFCS
SDGR
Price
$51.39
$15.13
Analyst Decision
Buy
Buy
Analyst Count
2
9
Target Price
$40.50
$21.00
AVG Volume (30 Days)
139.9K
866.1K
Earning Date
05-05-2026
05-05-2026
Dividend Yield
2.01%
N/A
EPS Growth
87.45
45.14
EPS
1.15
N/A
Revenue
$1,386,412,000.00
$255,869,000.00
Revenue This Year
$11.80
$0.76
Revenue Next Year
$8.77
$4.60
P/E Ratio
$45.34
N/A
Revenue Growth
10.62
23.29
52 Week Low
$26.11
$10.95
52 Week High
$54.42
$23.02

Technical Indicators

Market Signals
Indicator
UFCS
SDGR
Relative Strength Index (RSI) 53.14 45.00
Support Level $48.44 $14.61
Resistance Level $54.42 $16.47
Average True Range (ATR) 1.56 0.59
MACD -0.08 -0.11
Stochastic Oscillator 66.46 21.62

Price Performance

Historical Comparison
UFCS
SDGR

About UFCS United Fire Group Inc.

United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

Share on Social Networks: